Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 14, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, authorized by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,490,000 ordinary shares.
- Purchase Price: 1,326.0113 pence per share.
- Treasury Holdings: Following the purchase, the company holds 393,087,158 shares in Treasury.
- Treasury Percentage: Treasury shares represent 6.98% of total voting rights.
- Shares in Issue: 5,630,322,382 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares due to the repurchase of 1,490,000 shares on September 14, 2007. Consequently, the total number of shares held in Treasury increased to 393,087,158. The filing does not provide comparative data for prior periods regarding operational performance or financial results.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares in issue (5,630,322,382) for calculating ownership thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (393,087,158) and its impact on total voting rights (6.98%).
- Note that this filing is a notification of a specific transaction and does not contain quarterly or annual financial performance data.